Related Experiment Video
Updated: Jun 20, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Telomerase in cancer immunotherapy
Jun-Ping Liu1, Weisan Chen, Anthony P Schwarer
1Department of Immunology, Central Clinical School, Monash University, Commercial Road, Melbourne, Victoria 3004, Australia. jun-ping.liu@med.monash.edu.au
Abstract:
Telomerase is a common hallmark of cancer. Recent studies have shown promising developments in anti-telomerase cancer immunotherapy, using human telomerase reverse transcriptase (hTERT) as a tumor antigen. Vaccination, using hTERT peptides or adoptive transfer of hTERT-specific cytotoxic T lymphocytes, induces augmented tumor regression. CD8+ cytotoxic T lymphocytes, against various hTERT peptides, lyse hTERT-expressing tumor cells from multiple tissue origins. CD4+ helper T lymphocytes are also activated by peptides derived from hTERT. This article reviews the current and potential future applications of various hTERT peptide antigens as candidates for cancer vaccines, and explores the experimental challenges that needed to be faced to develop telomerase-based tumor vaccines to treat human cancer.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Replicative Cell Senescence
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment

